The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 12, 2016, Pages 2146-2161

  Chen, Yi Je ^a   Nguyen, Hai M ^a   Maezawa, Izumi ^b,c   Grössinger, Eva M ^a   Garing, April L ^a   Köhler, Ralf ^d   Jin, Lee Way ^b,c   Wulff, Heike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

Author keywords

KCa3.1; microglia activation; middle cerebral artery occlusion; potassium channel; TRAM 34

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCA3.1; UNCLASSIFIED DRUG; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTROPHYSIOLOGY; EXTERNAL CAROTID ARTERY; HIPPOCAMPAL SLICE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNAL CAROTID ARTERY; MACROPHAGE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY BURST; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL CULTURE; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; MACROPHAGE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROGENIC INFLAMMATION; PATHOLOGY;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MACROPHAGE ACTIVATION; MICE; MOLECULAR TARGETED THERAPY; NEUROGENIC INFLAMMATION; PYRAZOLES; STROKE;

EID: 85002045009     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15611434     Document Type: Article

References (39)

1. Nimmerjahn A, Kirchhoff F, and Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318.
2. Macrez R, Ali C, Toutirais O, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol 2011; 10: 471-480.
3. Iadecola C, and Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17: 796-808.
4. Kawabori M, and Yenari MA. The role of the microglia in acute cns injury. Metab Brain Dis 2015; 30: 381-392.
5. Prinz M, Priller J, Sisodia SS, et al. Heterogeneity of cns myeloid cells and their roles in neurodegeneration. Nat Neurosci 2011; 14: 1227-1235.
6. Turner RC, Dodson SC, Rosen CL, et al. The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. J Neurosurg 2013; 118: 1072-1085.
7. Fagan SC, Cronic LE, and Hess DC. Minocycline development for acute ischemic stroke. Transl Stroke Res 2011; 2: 202-208.
8. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-1410.
9. Fordyce CB, Jagasia R, Zhu X, et al. Microglia Kv1.3 channels contribute to their ability to kill neurons. J Neurosci 2005; 25: 7139-7149.
10. Kaushal V, Koeberle PD, Wang Y, et al. The Ca2activated Kchannel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 2007; 27: 234-244.
11. Maezawa I, Zimin P, Wulff H, et al. A-beta oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem 2011; 286: 3693-3706.
12. Feske S, Wulff H, and Skolnik EY. Ion channels in innate and adaptive immunity. Ann Rev Immunol 2015; 33: 291-353.
13. Kettenmann H, Hanisch UK, Noda M, et al. Physiology of microglia. Physiol Rev 2011; 91: 461-553.
14. Chen YJ, Raman G, Bodendiek S, et al. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab 2011; 31: 2363-2374.
15. Si H, Heyken WT, Wolfle SE, et al. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2-Activated K channel. Circ Res 2006; 99: 537-544.
16. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
17. Wulff H, Miller MJ, Haensel W, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca2-Activated K channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci USA 2000; 97: 8151-8156.
18. Menzies SA, Hoff JT, and Betz AL. Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. Neurosurgery 1992; 31: 100-106.
19. De Ryck M, Van Reempts J, Borgers M, et al. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke 1989; 20: 1383-1390.
20. Wulff H, Calabresi PA, Allie R, et al. The voltage-gated Kv1.3 K channel in effector memory T cells as new target for MS. J Clin Invest 2003; 111: 1703-1713.
21. Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 2005; 68: 1254-1270.
22. Chen YJ, Lam J, Gregory CR, et al. The Ca2-Activated K channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. PLoS ONE 2013; 8: e81006.
23. Fox C, Dingman A, Derugin N, et al. Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 2005; 25: 1138-1149.
24. Maezawa I, Nivison M, Montine KS, et al. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J 2006; 20: 797-799.
25. Schlattmann P, and Dirnagl U. Statistics in experimental cerebrovascular research: comparison of more than two groups with a continuous outcome variable. J Cereb Blood Flow Metab 2010; 30: 1558-1563.
26. McNeish AJ, Sandow SL, Neylon CB, et al. Evidence for involvement of both IKCa and SKCa channels in hyperpolarizing responses of the rat middle cerebral artery. Stroke 2006; 37: 1277-1282.
27. Rus H, Pardo CA, Hu L, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 2005; 102: 11094-11099.
28. Zaritsky JJ, Eckman DM, Wellman GC, et al. Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K current in K-mediated vasodilation. Circ Res 2000; 87: 160-166.
29. Boucsein C, Kettenmann H, and Nolte C. Electrophysiological properties of microglial cells in normal and pathologic rat brain slices. Eur J Neurosci 2000; 12: 2049-2058.
30. Lyons SA, Pastor A, Ohlemeyer C, et al. Distinct physiologic properties of microglia and blood-borne cells in rat brain slices after permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab 2000; 20: 1537-1549.
31. King B, Rizwan AP, Asmara H, et al. IKCa channels are a critical determinant of the slow ahp in ca1 pyramidal neurons. Cell Rep 2015; 11: 175-182.
32. Yenari MA, Kauppinen TM, and Swanson RA. Microglial activation in stroke: therapeutic targets. Neurotherapeutics 2010; 7: 378-391.
33. Chen YJ, Wallace BK, Yuen N, et al. Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke. Stroke 2015; 46: 237-244.
34. Girodet PO, Ozier A, Carvalho G, et al. Ca2-Activated K channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol 2013; 48: 212-219.
35. Di L, Srivastava S, Zhdanova O, et al. Inhibition of the K channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci USA 2010; 107: 1541-1546.
36. Ajmo CT Jr, Vernon DO, Collier L, et al. The spleen contributes to stroke-induced neurodegeneration. J Neurosci Res 2008; 86: 2227-2234.
37. Yilmaz G, Arumugam TV, Stokes KY, et al. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006; 113: 2105-2112.
38. Toyama K, Wulff H, Chandy KG, et al. The intermediate-conductance calcium-Activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 2008; 118: 3025-3037.
39. Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebocontrolled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011; 153: 92-104.